Symic Bio is a biopharmaceutical company developing a new category of therapeutics focused on matrix biology. The matrix is the non-cellular component of the body’s tissues and can be envisioned as the sponge-like environment. Research in recent decades has demonstrated the biological importance of the interactive and dynamic relationship between cells and their matrix environment. The Symic Bio platform of matrix regulators builds upon this research. This therapeutics bind to targets in the matrix damaged in response to injury or because of disease. They are designed to inhibit pathological inflammatory responses and to affect matrix degradation and structure.